News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Gaia Griguolo: TOP1 Mutations are more frequent after treatment with ADCs
Rachel O. Abelman
Jan 3, 2025, 15:31

Gaia Griguolo: TOP1 Mutations are more frequent after treatment with ADCs

Gaia Griguolo ,Medical Oncologist at the Department of Medical Oncology, Veneto Institute Oncology (IRCCS), shared a post on X:

“TOP1 Mutations are more frequent after treatment with ADCs and might be linked to resistance to SN38 and deruxtecan -potential mechanism for crossresistance?”

TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer

Authors: Rachel O. Abelman et al.

Gaia Griguolo

Aditya Bardia Andreas Varkaris Annika Putur Arielle Medford Beverly Moy Bogang Wu Bryanna Norden cancer Caroline Weipert Dejan Juric Elena Bitman Gaia Griguolo Geoffrey Fell Haley Barnes Laura M. Spring Leif W. Ellisen Neelima Vidula OncoDaily Oncology Rachel O. Abelman Ryan Corcoran Seth Wander Steven J. Isakoff Ting Liu Win Thant
Special Coverage
Blog
Jan 3, 2025, 15:31
Gaia Griguolo: TOP1 Mutations are more frequent after treatment with ADCs
Blog
Jan 3, 2025, 15:18
Elvina Almuradova: January is Cervical Cancer Awareness Month
Blog
Jan 3, 2025, 15:10
Unveiling the BGICC 2025 Congress Program
Career
Jan 3, 2025, 13:36
Cancer and Blood Specialists of Arizona Welcome Ronak Rakesh Shah to Its Physician Team
Insight
Jan 3, 2025, 13:31
Mitochondrial DNA's Role in Leukemia Development Explored by St. Jude Scientists
Science
Jan 3, 2025, 13:22
Myeloma Paper of the Day, January 3rd, suggested by Robert Orlowski
Blog
Jan 3, 2025, 13:00
The current treatment process with CAR T cells - Penn Medicine
Science
Jan 3, 2025, 12:51
Targeting Molecular Pathways to Control ICI Toxicities
Insight
Jan 3, 2025, 12:45
Drew Moghanaki: ‘Some pembrolizumab’ is better than ‘No pembrolizumab’ in patients scheduled for preop chemo
Insight
Jan 3, 2025, 12:40
Senthil Kumar: First-Line Therapy in RCC, Expanding Choices in a New Era
Insight
Jan 3, 2025, 12:36
Akhil Santhosh: Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer
Blog
Jan 3, 2025, 12:34
Here’s to another year of collaboration, progress, and making a difference - AIM-HI Accelerator Fund